scispace - formally typeset
Search or ask a question
Author

Raymond Bonnett

Bio: Raymond Bonnett is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Porphyrin & Chlorin. The author has an hindex of 40, co-authored 201 publications receiving 8538 citations. Previous affiliations of Raymond Bonnett include University of London & University of Cambridge.


Papers
More filters
Book
07 Aug 2000
TL;DR: The chemistry of Haematoporphyrin Derivative (HpD) and second generation photosensitisers are discussed in this paper, as well as other examples of photodynamic therapy.
Abstract: 1. Introduction, 2. Physical Matters, 3. Singlet Oxygen, 4. Photodynamic Action, 5. Some Other Examples of Photodynamic Therapy, 6. The Chemistry of Haematoporphyrin Derivative (HpD), 7. Second Generation Photosensitisers, 8. Porphyrin Photosensitisers, 9. Chlorins and Bascteriochlorins, 10. Phthalocyanines and Napthalocyanines, 11. Other Photosynthesises, 12. Photobleaching, 13. Biological Aspects, 14. Clinical and Commercial Developments

690 citations

Journal ArticleDOI
TL;DR: Four new hydroporphyrins related to the tetra(hydroxyphenyl)porphyrins show the expected strong absorption bands in the red region of the visible spectrum and are found to be very effective tumour photosensitizers.
Abstract: Four new hydroporphyrins [the o, m and p isomers of 5,10,15,20-tetra(hydroxyphenyl)chlorin and 5,10,15,20-tetra(m-hydroxyphenyl)bacteriochlorin] related to the tetra(hydroxyphenyl)porphyrins have been prepared. They show the expected strong absorption bands in the red region of the visible spectrum and are found to be very effective tumour photosensitizers.

320 citations

Journal ArticleDOI
TL;DR: Four patients underwent intraoperative photodynamic therapy after surgery with meso-tetra-(hydroxyphenyl)-chlorin (mTHPC-PDT) for diffuse malignant mesothelioma and one patient succumbed from aspiration pneumonia.
Abstract: Four patients underwent intraoperative photodynamic therapy after surgery with meso-tetra-(hydroxyphenyl)-chlorin (mTHPC-PDT) for diffuse malignant mesothelioma. Preliminary procedures were performed in two patients in order to establish the efficacy of mTHPC-PDT and to optimise its tumoricidal effect. The tumoricidal effect was related to the mTHPC dose, light dose and the time interval between sensitation and activation. 0.3 mg kg-1 mTHPC activated after 48 h with 10 Joules cm-2 of non-thermal laser light at 650 nm resulted in a 10 mm deep tumour infarction, due to tumour vessel necrosis and thrombosis. The mTHPC tissue concentration was up to 14 times higher in the tumour than in normal tissues. Skin photosensitivity was mild, dose dependent and occurred 3 to 10 days after administration of mTHPC. According to the results obtained, intraoperative mTHPC-PDT was performed following pleuropneumonectomy in two, pleurectomy and lobectomy in one and pleurectomy in one patient. Ten Joules cm-2 were delivered to the diaphragm and the costophrenic sulcus and 5 Joules cm-2 to the remaining thoracic cavity. The postoperative course was marked by loss of appetite, fluid retention, hypoproteinemia and severe chest pain. One patient succumbed from aspiration pneumonia. The remaining patients developed no neural or vascular alterations and no bronchial stump insufficiency during follow-up. mTHPC-PDT following surgical tumour resection deserves further evaluation in good risk patients with diffuse malignant mesothelioma.

223 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: PDT is being tested in the clinic for use in oncology — to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin.
Abstract: The therapeutic properties of light have been known for thousands of years, but it was only in the last century that photodynamic therapy (PDT) was developed. At present, PDT is being tested in the clinic for use in oncology--to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin. How does PDT work, and how can it be used to treat cancer and other diseases?

5,041 citations

Journal ArticleDOI
TL;DR: An overview of the field of semiconductor photocatalysis can be found in this paper, where a brief examination of its roots, achievements and possible future is presented, and the semiconductor titanium dioxide (TiO 2 ) features predominantly in past and present work.
Abstract: The interest in heterogeneous photocatalysis is intense and increasing, as shown by the number of publications on this theme which regularly appear in this journal, and the fact that over 2000 papers have been published on this topic since 1981. This article is an overview of the field of semiconductor photocatalysis : a brief examination of its roots, achievements and possible future. The semiconductor titanium dioxide (TiO 2 ) features predominantly in past and present work on semiconductor photocatalysis; as a result, in the most of the examples selected in this overview to illustrate various points the semiconductor is TiO 2 .

3,245 citations

Journal ArticleDOI
TL;DR: In this article, the photophysical properties of singlet molecular oxygen and of the photosensitizers used in its generation are examined and compared, with particular focus on its role in wastewater treatment, fine chemical synthesis, and photodynamic therapy.

2,382 citations

Journal ArticleDOI
TL;DR: The development of the PPTT method is discussed with special emphasis on the recent in vitro and in vivo success using gold nanospheres coupled with visible lasers and gold nanorods and silica–gold nanoshells coupled with near-infrared lasers.
Abstract: The use of lasers, over the past few decades, has emerged to be highly promising for cancer therapy modalities, most commonly the photothermal therapy method, which employs light absorbing dyes for achieving the photothermal damage of tumors, and the photodynamic therapy, which employs chemical photosensitizers that generate singlet oxygen that is capable of tumor destruction. However, recent advances in the field of nanoscience have seen the emergence of noble metal nanostructures with unique photophysical properties, well suited for applications in cancer phototherapy. Noble metal nanoparticles, on account of the phenomenon of surface plasmon resonance, possess strongly enhanced visible and near-infrared light absorption, several orders of magnitude more intense compared to conventional laser phototherapy agents. The use of plasmonic nanoparticles as highly enhanced photoabsorbing agents has thus introduced a much more selective and efficient cancer therapy strategy, viz. plasmonic photothermal therapy (PPTT). The synthetic tunability of the optothermal properties and the bio-targeting abilities of the plasmonic gold nanostructures make the PPTT method furthermore promising. In this review, we discuss the development of the PPTT method with special emphasis on the recent in vitro and in vivo success using gold nanospheres coupled with visible lasers and gold nanorods and silica-gold nanoshells coupled with near-infrared lasers.

2,024 citations